GSK Canada today announced the approval of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) in a prefilled syringe. This new presentation removes the need to reconstitute separate vials prior to administration, simplifying the vaccine administration process for healthcare professionals.

Approval of the new prefilled syringe presentation is based on data confirming technical comparability between the new and existing vaccine presentations. The prefilled syringe presentation is expected to be available across Canada beginning in early 2027.